Several randomized controlled trials have investigated the effects of a number of drugs on the reduction of fracture risk in women with postmenopausal osteoporosis. Meanwhile, algorithms have become available to identify women at the highest risk of fractures. In this context, this article outlines patient- and drug-related determinants that contribute to the clinical decision about initiating and choosing drug therapy for the prevention of fractures.
- Piet P Geusens
- Christian H Roux
- Marc C Hochberg
